296 related articles for article (PubMed ID: 33913648)
1. Polypill in Persons without Cardiovascular Disease.
Gallieni M; Paik JM; Fiorina P
N Engl J Med; 2021 Apr; 384(17):1673-1674. PubMed ID: 33913648
[No Abstract] [Full Text] [Related]
2. Polypill in Persons without Cardiovascular Disease.
Cainzos-Achirica M
N Engl J Med; 2021 Apr; 384(17):1675-1676. PubMed ID: 33913652
[No Abstract] [Full Text] [Related]
3. Polypill in Persons without Cardiovascular Disease.
Wald N; Wald D; Law M
N Engl J Med; 2021 Apr; 384(17):1675. PubMed ID: 33913651
[No Abstract] [Full Text] [Related]
4. Polypill in Persons without Cardiovascular Disease.
Messerli FH; Brguljan J; Bangalore S
N Engl J Med; 2021 Apr; 384(17):1674-1675. PubMed ID: 33913650
[No Abstract] [Full Text] [Related]
5. Polypill in Persons without Cardiovascular Disease.
Alam A; Carey SA; Hall SA
N Engl J Med; 2021 Apr; 384(17):1674. PubMed ID: 33913649
[No Abstract] [Full Text] [Related]
6. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
[TBL] [Abstract][Full Text] [Related]
7. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
[TBL] [Abstract][Full Text] [Related]
8. Polypill in Persons without Cardiovascular Disease. Reply.
Yusuf S; Joseph P; Pais P
N Engl J Med; 2021 Apr; 384(17):1676-1677. PubMed ID: 33913653
[No Abstract] [Full Text] [Related]
9. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
[TBL] [Abstract][Full Text] [Related]
10. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
Carey KM; Comee MR; Donovan JL; Kanaan AO
Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437
[TBL] [Abstract][Full Text] [Related]
11. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
[TBL] [Abstract][Full Text] [Related]
12. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
Zomer E; Owen A; Magliano DJ; Ademi Z; Reid CM; Liew D
Am J Cardiovasc Drugs; 2013 Apr; 13(2):121-8. PubMed ID: 23532687
[TBL] [Abstract][Full Text] [Related]
13. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J
Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098
[TBL] [Abstract][Full Text] [Related]
14. [The polypill: optimal strategy for reduction of cardiovascular disease].
Nathoe HM; Doevendans PA
Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1740. PubMed ID: 16114290
[TBL] [Abstract][Full Text] [Related]
15. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
[TBL] [Abstract][Full Text] [Related]
16. Improving cardiovascular protection: focus on a cardiovascular polypill.
Barrios V; Escobar C
Future Cardiol; 2016 Mar; 12(2):181-96. PubMed ID: 26652213
[TBL] [Abstract][Full Text] [Related]
17. Polypill for cardiovascular disease prevention.
Dalton AR
JAMA; 2013 Aug; 310(7):749. PubMed ID: 23989135
[No Abstract] [Full Text] [Related]
18. Mesoporous silica nanoparticles as a new carrier methodology in the controlled release of the active components in a polypill.
Doadrio AL; Sánchez-Montero JM; Doadrio JC; Salinas AJ; Vallet-Regí M
Eur J Pharm Sci; 2017 Jan; 97():1-8. PubMed ID: 27818251
[TBL] [Abstract][Full Text] [Related]
19. Polypill for cardiovascular disease prevention--reply.
Smith R; McCready T; Yusuf S
JAMA; 2013 Aug; 310(7):749-50. PubMed ID: 23989317
[No Abstract] [Full Text] [Related]
20. [The Polypill: between myths and reality in the treatment of type 2 diabetes mellitus].
Ruiz J; Egli M
Rev Med Suisse; 2006 May; 2(68):1480-2, 1484-5. PubMed ID: 16783994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]